Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 8 | 2021 | 1274 | 0.940 |
Why?
|
| Antihypertensive Agents | 6 | 2021 | 392 | 0.890 |
Why?
|
| Renin | 1 | 2012 | 89 | 0.400 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 30 | 0.350 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 121 | 0.350 |
Why?
|
| Leadership | 1 | 2010 | 226 | 0.300 |
Why?
|
| Societies, Medical | 1 | 2010 | 673 | 0.270 |
Why?
|
| Ethical Review | 1 | 2004 | 3 | 0.230 |
Why?
|
| Ethics Committees, Research | 1 | 2004 | 34 | 0.220 |
Why?
|
| Research Subjects | 1 | 2004 | 55 | 0.220 |
Why?
|
| Blood Pressure | 5 | 2021 | 1314 | 0.210 |
Why?
|
| Fumarates | 2 | 2012 | 15 | 0.190 |
Why?
|
| Drug Recalls | 1 | 2020 | 4 | 0.180 |
Why?
|
| Amides | 2 | 2012 | 82 | 0.180 |
Why?
|
| Drug Contamination | 1 | 2020 | 36 | 0.180 |
Why?
|
| Drug Industry | 1 | 2020 | 45 | 0.180 |
Why?
|
| Drug Therapy, Combination | 4 | 2012 | 1147 | 0.180 |
Why?
|
| Drug Approval | 1 | 2020 | 39 | 0.180 |
Why?
|
| Quality Control | 1 | 2020 | 116 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 51 | 0.170 |
Why?
|
| Carcinogens | 1 | 2020 | 152 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 147 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 366 | 0.160 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2016 | 51 | 0.150 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 113 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 621 | 0.120 |
Why?
|
| Renin-Angiotensin System | 2 | 2012 | 95 | 0.120 |
Why?
|
| White Matter | 1 | 2016 | 180 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 432 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 34 | 0.100 |
Why?
|
| Lipids | 1 | 2013 | 512 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 266 | 0.090 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 68 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2125 | 0.080 |
Why?
|
| Valine | 1 | 2009 | 106 | 0.080 |
Why?
|
| Tetrazoles | 1 | 2009 | 63 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1823 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1084 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 713 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 438 | 0.070 |
Why?
|
| Humans | 12 | 2022 | 122349 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 816 | 0.060 |
Why?
|
| Scientific Misconduct | 1 | 2004 | 6 | 0.060 |
Why?
|
| Human Experimentation | 1 | 2004 | 38 | 0.060 |
Why?
|
| Research Personnel | 1 | 2004 | 117 | 0.050 |
Why?
|
| Lisinopril | 1 | 2002 | 25 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 64 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2004 | 376 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1570 | 0.050 |
Why?
|
| United States | 2 | 2020 | 10494 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 210 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 234 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2002 | 258 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 446 | 0.040 |
Why?
|
| Body Height | 1 | 2021 | 205 | 0.040 |
Why?
|
| Aged | 5 | 2016 | 18799 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1167 | 0.040 |
Why?
|
| Systole | 1 | 2016 | 197 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 389 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2011 | 12049 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 411 | 0.030 |
Why?
|
| Azetidines | 1 | 2013 | 55 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 57 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 75 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2013 | 95 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 480 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 190 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2013 | 178 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 3307 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 521 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 514 | 0.020 |
Why?
|
| Male | 5 | 2016 | 59559 | 0.020 |
Why?
|
| Valsartan | 1 | 2009 | 21 | 0.020 |
Why?
|
| Female | 5 | 2016 | 64923 | 0.020 |
Why?
|
| Adult | 3 | 2021 | 28764 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5013 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 4643 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6182 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 9903 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1679 | 0.020 |
Why?
|
| Middle Aged | 3 | 2013 | 25655 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6293 | 0.020 |
Why?
|
| Celecoxib | 1 | 2002 | 31 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3448 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 60 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 88 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 222 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 158 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 1315 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 303 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2002 | 300 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 584 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1521 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 18959 | 0.000 |
Why?
|